

Special Issue

Drug Candidates for the Prevention and Treatment of Cardiovascular Diseases in Patients with Diabetes Mellitus

Message from the Guest Editor

Diabetes mellitus (DM) has already evolved into an epidemic in developing countries, and especially in the western world. It is well-known that diabetic patients have a 2- to 4-fold higher risk for cardiovascular diseases (CVDs). Moreover, the presence of DM remarkably increases the incidence of cardiovascular events in patients with established CVDs despite the administration of optimum pharmaceutical therapy. The re-vascularization procedures in coronary and peripheral arteries are characterized by a higher incidence of complications in patients with DM than their non-diabetic counterparts. Therefore, there is still an increasing need to develop and apply more effective medications for primary and secondary prevention of CVDs (ischemic and non-ischemic) in the DM population. The aim of the present Special Issue is to attract more than 10 high-quality papers that focus on drugs with potentiality to contribute to CVD prevention and treatment in diabetic patients.

Guest Editor

Dr. Nikolaos Kadoglou

Medical School, University of Cyprus, 2029 Nicosia, Cyprus

Deadline for manuscript submissions

closed (26 February 2024)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/156877

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)